Stocktoria
OMEROS CORP OMER
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2009-10-08
OMEROS CORP financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $81.3M | $119.5M | $114.9M | $112.7M | $118.8M |
| SG&A expense | $41.5M | $47.4M | $49.7M | $50.7M | $54.8M |
| Operating income | -$122.8M | -$167.0M | -$164.5M | -$163.4M | -$173.6M |
| Interest expense | — | — | $30.8M | $22.7M | $19.7M |
| Income tax | $2.0M | $2.3M | $0 | $0 | $0 |
| Net income | -$3.4M | -$156.8M | -$117.8M | $47.4M | $194.2M |
| EPS (diluted) | $-0.05 | $-2.70 | $-1.88 | $0.76 | $3.12 |
| Operating cash flow | -$116.1M | -$148.8M | $74.7M | -$86.5M | -$109.7M |
| Free cash flow | -$116.2M | -$149.0M | $74.3M | -$86.6M | -$110.0M |
| Cash & equivalents | $9.7M | $3.4M | $7.1M | $11.0M | $100.8M |
| Inventory | $0 | — | — | — | — |
| Total assets | $325.6M | $277.1M | $378.3M | $591.0M | $419.3M |
| Shareholders' equity | -$121.2M | -$182.6M | -$25.0M | $85.7M | $23.8M |
Source: SEC EDGAR filings · CIK 0001285819 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.